Thrivent Financial for Lutherans
APLS

Thrivent Financial for Lutherans’s Apellis Pharmaceuticals APLS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,407
Closed -$2.75M – 2599
2026
Q1 		$2.75M Buy
+68,407
New +$1.47M 0.01% 1218
2024
Q1 		– Sell
-97,716
Closed -$5.85M – 2508
2023
Q4 		$5.85M Buy
97,716
+18,255
+23% +$926K 0.01% 799
2023
Q3 		$3.02M Buy
+79,461
New +$3.49M 0.01% 1030

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Thrivent Financial for Lutherans's APLS Position: Q2 2026 in Review

Thrivent Financial for Lutherans sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 68,407 shares — an estimated $2.75M sold.

Thrivent Financial for Lutherans first reported a position in APLS in Q3 2023 and held it in 3 quarters. The position peaked at $5.85M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Thrivent Financial for Lutherans reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 68,407 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.75M.
  • Thrivent Financial for Lutherans first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's Apellis Pharmaceuticals position peaked at $5.85M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.